AV Comments on Proposed Rule for Revision to Rules of Practice before the Patent Trial and Appeal Board

In a recent comment letter to the U.S. Patent and Trademark Office (USPTO), Arnold Ventures does not support the proposed rule and urges the USPTO to withdraw it. If adopted, the rule would limit the use in the pharmaceutical sector of the inter partes review (IPR) process for challenging invalid patents at the Patent Trials and Appeals Board (PTAB), which would extend brand name pharmaceutical company monopolies and lead to higher prices for patients, employers, and taxpayers. This is in direct conflict with the administration’s expressed priority to deliver lower drug prices to American patients by accelerating competition.